- A phase I cell dose escalation scheme will be performed using 4 dose levels (3 x 105 transduced T cells/kg; 1 x 106 transduced T cells/kg; 3 x 106 transduced T cells/kg; and 1 x 107 transduced T cells/kg ( 20%)). If 2/6 patients have DLT at dose level 1, safety will be evaluated in a de-escalated dose of 1 x 105 transduced T cells/kg ( 20%)). Once the maximum tolerated dose (or highest level evaluated) is reached, enrollment into an expansion cohort of a total of 17 patients at MTD in two strata will proceed to provide additional information regarding the feasibility, safety and efficacy of this treatment. Patients who have previously received CD19 CAR T cells will be evaluated separately from CARna(SqrRoot) ve patients as response may be different in these two groups.